Close
Nordic 9Nordic 9

Charles River Laboratories (investor - Corporate Investor)

United States criver.com
See something wrong or missing? Let us know
Offices:Boston

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries.

Average round investment:48.99M USD
Average number per year:1.0
Distribution: 2024 (1)2022 (1)2021 (1)
Portfolio companies: Ireland DeciphexUnited Kingdom bit.bio
Mostly invests in: Ireland Ireland (2) Software Services (3)

3 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Charles River Laboratories

Name Criteria
Canada Georgian
92%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Software Services, Health services, Competitive Intelligence
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Honeywell Ventures
91%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Software Services, Health services, Competitive Intelligence
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United States Cleveland Avenue
91%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Software Services, Health services, Biotech, Competitive Intelligence
  • Similar business models: B2B, SAAS
  • Common investees countries: Ireland, United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United Kingdom Tom Chapman
90%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Software Services, Health services, Competitive Intelligence
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Guggenheim Investments
90%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Software Services, Health services, Competitive Intelligence
  • Similar business models: B2B, SAAS
  • Common investees countries: Ireland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Leaps by Bayer
90%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Software Services, Health services, Competitive Intelligence
  • Similar business models: B2B, SAAS
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
Netherlands Gilde Healthcare
89%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Software Services, Health services, Biotech
  • Similar business models: B2B, SAAS
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Germany Vogel Ventures GmbH
89%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Software Services, Health services, Competitive Intelligence
  • Similar business models: B2B, SAAS
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Switzerland HBM Healthcare Investments
89%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Software Services, Health services, Biotech
  • Similar business models: B2B, SAAS
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Sweden IK Investment Partners
88%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Software Services, Health services, Biotech, Competitive Intelligence
  • Similar business models: B2B, SAAS
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
Top